Obesity Surgery

, Volume 23, Issue 7, pp 867–873 | Cite as

Preoperative Fasting Plasma C-Peptide Level May Help to Predict Diabetes Outcome After Gastric Bypass Surgery

  • E. O. Aarts
  • J. Janssen
  • I. M. C. Janssen
  • F. J. Berends
  • D. Telting
  • H. de Boer
Original Contributions



To evaluate whether preoperative measurement of fasting plasma C-peptide levels is useful to predict diabetes outcome after Roux-en-Y gastric bypass (RYGB) surgery.

Materials and Methods

Diabetes outcome after RYGB was evaluated in 126 obese patients: 41 non-diabetic controls (NDC), 29 with impaired glucose tolerance (IGT) and 56 had type 2 diabetes mellitus (T2DM). Body weight, fasting plasma glucose, fasting C-peptide levels, and HbA1c were measured at baseline and 3.6 ± 0.16 years after GBS. Complete resolution of diabetes was defined as: fasting glucose <7.0 mmol/l, HbA1c <6.5 %, achieved without anti-diabetic medication.


Patients with complete resolution of diabetes had a more recent diagnosis of T2DM, lower preoperative HbA1c levels and lower daily doses of metformin and insulin use. These parameters were related to postoperative HbA1c levels but they failed to mark the specific patients who had not reached complete resolution of T2DM. Fasting preoperative C-peptide levels had better predictive power: 90 % of T2DM patients with preoperative fasting C-peptide levels >1.0 nmol/l achieved a postoperative HbA1c <6.5 %, and 74 % achieved complete resolution of their diabetes. In contrast, none of the T2DM patients with a preoperative fasting C-peptide <1.0 nmol/l attained these goals.


A preoperative fasting plasma C-peptide level <1.0 nmol/l in severely obese T2DM patients indicates partial β-cell failure, and is associated with a markedly reduced chance of complete resolution of T2DM after RYGB. We therefore advocate measuring C-peptide levels in all diabetic patients up for bariatric surgery to improve the prediction of outcome.


Obesity C-peptide Roux-en-Y gastric bypass Type 2 diabetes mellitus 


Conflict of interest

E. O. Aarts, J. Janssen, D. Telting and H. de Boer MD have no conflicts of interest to declare. I. M. C. Janssen and F J. Berends are both consultants for Johnson & Johnson.


  1. 1.
    Bult MJF et al. Surgical treatment of obesity. European Journal of Endocrinology. 2008;158:135–45.PubMedCrossRefGoogle Scholar
  2. 2.
    Levy P, Fried M, et al. The comparative effects of bariatric surgery on weight and type 2 diabetes. Obes Surg. 2007;17:1248–56.PubMedCrossRefGoogle Scholar
  3. 3.
    Buchwald H, Estok R, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–256 e5.PubMedCrossRefGoogle Scholar
  4. 4.
    Vetter ML, Cardillo S et al. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus, Ann Intern Med 2009; 20;150(2):94–103.Google Scholar
  5. 5.
    Wahren J, Ekberg K, Jornvall H. C-peptide is a bioactive peptide. Diabetologica. 2007;50:5003–9.CrossRefGoogle Scholar
  6. 6.
    Hills CE, Brunskill NJ. Cellular and physiological effects of C-peptide. Cli Sci. 2009;116:565–74.CrossRefGoogle Scholar
  7. 7.
    Luppi P, Cifarelli V, Wahren J. C-peptide and long term complications of diabetes. Pediatr Diabetes. 2011;12:276–92.PubMedCrossRefGoogle Scholar
  8. 8.
    Pories WJ et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Colquitt JL, Picot J, et al. Surgery for obesity. Cochrane Database Syst Rev. 2009;2:CD003641.PubMedGoogle Scholar
  10. 10.
    Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hama G, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467–84. discussion 84–5.PubMedGoogle Scholar
  11. 11.
    Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg. 2003;237:751–6. discussion 757–8.PubMedGoogle Scholar
  12. 12.
    Brandenburg D. History and diagnostic significance of C-peptide. Exp Diabetes Res 2008: 576862.Google Scholar
  13. 13.
    Thaler JP, Cummings DE. Minireview: hormonal and metabolic mechanisms of Diabetes remission after Gastrointestinal Surgery. Endocrinology. 2009;150:2518–25.PubMedCrossRefGoogle Scholar
  14. 14.
    Gastrointestinal Surgery for Severe Obesity National Institutes of Health: Consensus Development Conference Statement, March 25–27, 1991.Google Scholar
  15. 15.
    Sturm R. Increases in clinically severe obesity in the United States. Arch intern med. 2003;163:2146–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Bose M et al. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence. Obes Surg. 2009;19:217–29.PubMedCrossRefGoogle Scholar
  17. 17.
    Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Eng J Med. 2004;351:2683–93.CrossRefGoogle Scholar
  18. 18.
    Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.PubMedCrossRefGoogle Scholar
  19. 19.
    Keating CL, Dixon JB, Moodie ML, et al. Cost-efficacy of surgically induced weight loss for the management of type 2 diabetes: a randomized controlled trial. Diabetes Care. 2009;32:580–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • E. O. Aarts
    • 1
  • J. Janssen
    • 1
  • I. M. C. Janssen
    • 1
  • F. J. Berends
    • 1
  • D. Telting
    • 2
  • H. de Boer
    • 3
  1. 1.Department of SurgeryRijnstate HospitalArnhemThe Netherlands
  2. 2.Department of Clinical ChemistryRijnstate HospitalArnhemThe Netherlands
  3. 3.Department of Internal MedicineRijnstate HospitalArnhemThe Netherlands

Personalised recommendations